TABLE 1.

Overview of EPT schemes and their characteristics.

	Scheme 1		Scheme 2		Scheme 3
	HLA typing	Crossmatching	HLA-specific antibody detection	HLA-specific antibody identification	Patient-based cases
Dispatches per year	4	4	1	1	3
Numbers and types of samples per dispatch	3 tubes of blood	3 tubes of blood 3 serum samples	12 vials of serum in one shipment	12 vials of serum in one shipment	n.a
Period until deadline	2 weeks	2 weeks	4–5 months	4–5 months	2 weeks
Entrance of results	Manually on the website	Manually on the website	Manually on the website	Manually on the website	By e-mail
Entrance of results	Eurotransplant match determinants	Positive/negative	Positive/negative	Specificities for HLA-A, -B, -C, -DR, -DQ, and -DP	Answer and motivation related to the case
Time for the assessment of the results	2 weeks; reports are published on the EPT website	2 weeks; reports are published on the EPT website	1 month; reports are published on the EPT website	1 month; reports are published on the EPT website	2 months; the summary is published on the EPT website
Assessment method	Based on 75% consensus	Based on 75% consensus	Detection 75% consensus	Identification CDC: 75% consensus; bead-based methods: 95% consensus	Not assessed; a summary with all the results is published
Maximum yearly discrepancy rate	10%	15%	20%	25%	n.a
Methods assessed	CDC and low-resolution HLA typing	CDC	Bead-based methods, CDC	CDC, single antigen bead assays and complement-dependent SA bead assays	n.a
Number of participants in 2023	68	66	76	76	52